ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,081 to 1,100 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
C. Difficile Vaccine Group vs Placebo Group: Number of Participants With Symptomatic Polymerase Chain Reaction (PCR)-Confirmed Primary C. Difficile Infection (CDI) Cases34 of 6,173

16 of 3,085

0.0 points

-0.3 to 0.3

9,258NCT01887912

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

With Metabolic Syndrome vs Without Metabolic Syndrome: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Metabolic Syndrome)92 of 1,716

852 of 7,535

-5.9 points

-7.2 to -4.6

9,251NCT01252563

Amlodipine 10mg Drug Use Investigation

With Chronic Kidney Disease vs Without Chronic Kidney Disease: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Chronic Kidney Disease)24 of 1,034

920 of 8,217

-8.9 points

-9.9 to -7.6

9,251NCT01252563

Amlodipine 10mg Drug Use Investigation

With Diabetes Mellitus vs Without Diabetes Mellitus: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Diabetes Mellitus)52 of 2,247

892 of 7,004

-10.4 points

-11.4 to -9.4

9,251NCT01252563

Amlodipine 10mg Drug Use Investigation

With Myocardial Infarction vs Without Myocardial Infarction: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Myocardial Infarction)1 of 55

943 of 9,196

-8.4 points

-10.1 to -0.6

9,251NCT01252563

Amlodipine 10mg Drug Use Investigation

Prasugrel vs Clopidogrel: serious adverse events1,573 of 4,623

1,594 of 4,617

-0.5 points

-2.4 to 1.4

9,240NCT00699998

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Tranexamic Acid vs Placebo: Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery339 of 4,641

368 of 4,573

-0.7 points

-1.8 to 0.3

9,214NCT03364491

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

C. Difficile Vaccine Group vs Placebo Group: deaths from any cause255 of 6,113

127 of 3,057

0.0 points

-0.9 to 0.9

9,170NCT01887912

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

C. Difficile Vaccine Group vs Placebo Group: serious adverse events1,662 of 6,113

851 of 3,057

-0.6 points

-2.6 to 1.3

9,170NCT01887912

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Fluzone® High Dose vs Fluzone®: serious adverse events493 of 6,108

236 of 3,050

0.3 points

-0.9 to 1.5

9,158NCT00976027

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

Automated Call vs Text Messaging: Percentage of Tested Patients12 of 4,489

25 of 4,631

-0.3 points

-0.6 to -0.0

9,120NCT05315908

COVID-19 Testing in Underserved and Vulnerable Populations

Automated Call vs Text Messaging: Number (%) Tested (Total and by Clinic)12 of 4,489

25 of 4,631

-0.3 points

-0.6 to -0.0

9,120NCT05315908

COVID-19 Testing in Underserved and Vulnerable Populations

S-268019-b vs Placebo: Number of Participants With First Occurrence of SARS-CoV-2 RT-PCR-Positive Severe COVID-19 in the Initial Vaccination Period With Onset at Least 14 Days Following Second Vaccination Regardless of Serostatus or PCR Status at Baseline0 of 6,049

1 of 3,034

-0.0 points

-0.2 to 0.0

9,083NCT05212948

A Study of S-268019 for the Prevention of COVID-19

S-268019-b vs Placebo: Number of Participants With First Occurrence of SARS-CoV-2 RT-PCR-Positive Symptomatic COVID-19 in the Initial Vaccination Period Regardless of Serostatus or PCR Status at Baseline With Onset at Least 14 Days Following Second Vaccination331 of 6,023

242 of 3,012

-2.5 points

-3.7 to -1.4

9,035NCT05212948

A Study of S-268019 for the Prevention of COVID-19

Irbesartan vs Placebo: First Hospitalisation for Heart Failure (HF)482 of 4,518

551 of 4,498

-1.6 points

-2.9 to -0.3

9,016NCT00249795

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

Irbesartan vs Placebo: Death From Any Cause949 of 4,518

929 of 4,498

0.4 points

-1.3 to 2.0

9,016NCT00249795

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

Irbesartan vs Placebo: First Occurrence of Stroke379 of 4,518

411 of 4,498

-0.7 points

-1.9 to 0.4

9,016NCT00249795

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

Irbesartan vs Placebo: First Hospitalisation for Other Cardiovascular (CV) Cause1,186 of 4,518

1,174 of 4,498

0.2 points

-1.7 to 2.0

9,016NCT00249795

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

Irbesartan vs Placebo: First Occurrence of Any Heart Failure (HF) Episode699 of 4,518

767 of 4,498

-1.6 points

-3.1 to -0.1

9,016NCT00249795

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

Irbesartan vs Placebo: serious adverse events1,409 of 4,518

1,446 of 4,498

-1.0 points

-2.9 to 1.0

9,016NCT00249795

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=55

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01887912-b6fb6639",
        "title": "C. Difficile Vaccine Group vs Placebo Group: Number of Participants With Symptomatic Polymerase Chain Reaction (PCR)-Confirmed Primary C. Difficile Infection (CDI) Cases",
        "summary": "34 of 6173 against 16 of 3085; risk difference 0.0 points, 95% interval -0.3 to 0.3; NCT01887912, Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection",
        "record": "/library/comparisons/NCT01887912-b6fb6639",
        "nct_id": "NCT01887912",
        "kind": "outcome",
        "participants": 9258,
        "risk_difference": {
          "value": 0.0003214710582840896,
          "lower": -0.003260031682308312,
          "upper": 0.0032731228641439485
        },
        "group_1": "34 of 6,173",
        "group_2": "16 of 3,085",
        "difference": "0.0 points",
        "interval": "-0.3 to 0.3",
        "trial_title": "Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection"
      },
      {
        "id": "NCT01252563-4a1fd637",
        "title": "With Metabolic Syndrome vs Without Metabolic Syndrome: Number of Participants Who Achieved the Target Blood Pressure: With/Without Complication (Metabolic Syndrome)",
        "summary": "92 of 1716 against 852 of 7535; risk difference -5.9 points, 95% interval -7.2 to -4.6; NCT01252563, Amlodipine 10mg Drug Use Investigation",
        "record": "/library/comparisons/NCT01252563-4a1fd637",
        "nct_id": "NCT01252563",
        "kind": "outcome",
        "participants": 9251,
        "risk_difference": {
          "value": -0.05945927551766968,
          "lower": -0.07162466373102162,
          "upper": -0.04585780475212915
        },
        "group_1": "92 of 1,716",
        "group_2": "852 of 7,535",
        "difference": "-5.9 points",
        "interval": "-7.2 to -4.6",
        "trial_title": "Amlodipine 10mg Drug Use Investigation"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=56",
  "request_id": "UmKl5Yq692GyMYrg"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?